Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

PLSE

+ Watchlist+ Portfolio

Pulse Biosciences, Inc

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$44.84
52-Week Range
$12.56 – $58.94
Market Cap
$3.37B
P/E (TTM)
—
EPS (TTM)
-1.21
Dividend Yield
0.00%
Advanced Metrics
Price/Book
18.30
PEG Ratio
—
Return on Equity
-60.61%
Return on Assets
-35.27%
Gross Margin
26.77%
Operating Margin
-5861.24%
Profit Margin
0.00%
Current Ratio
14.35
Debt/Equity
0.03
Total Debt
$6.36M
Free Cash Flow
$-34.23M
Revenue Growth
359.30%
Earnings Growth
—
Enterprise Value
$3.19B

Market Snapshot

About

Pulse Biosciences, Inc. develops and commercializes proprietary Nano-Pulse Stimulation (NPS) technology, a novel energy modality that delivers nanosecond-duration pulses of electrical energy to non-thermally clear cells while preserving the surrounding architecture. Headquartered in Hayward, California, the company focuses on dermatology and medical aesthetics applications. Its flagship product, CellFX System, received FDA clearance in 2021 for the treatment of seborrheic keratosis, a common non-cancerous skin lesion. Pulse Biosciences targets the dermatology market with its proprietary platform technology, which creates cellular disruption through an electrical field rather than thermal damage associated with traditional ablation methods. The company operates as a commercial-stage medical technology firm, having transitioned from development to market adoption of its NPS technology. In 2023, Pulse Biosciences expanded its product portfolio with additional FDA clearances for the CellFX System to treat skin lesions and general dermatological procedures. The company collaborates with dermatologists and plastic surgeons to establish clinical evidence and expand its commercial footprint in the aesthetic and therapeutic dermatology sectors. Pulse Biosciences holds an extensive intellectual property portfolio with numerous patents covering its NPS technology platform. As a growth-stage company, it continues to invest in clinical studies, regulatory approvals, and commercial infrastructure to support broader adoption of its technology across dermatological applications.